Cite
HARVARD Citation
Ascierto, P. et al. (n.d.). Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet oncology. 18 (5), pp. 611-622. [Online].